We provide you with 20 years of free, institutional-grade data for LOGC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of LOGC. Explore the full financial landscape of LOGC stock.
| Reported Date | CIK | Ticker | Type |
|---|
LogicBio Therapeutics, Inc(NASDAQ:LOGC) 
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic eff...
Website: http://www.logicbio.com
Founded: 2014
Full Time Employees: 39 (May 2021)
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about LOGC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.